Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pai Holdings Pharm	TENSILON PRESERVATIVE FREE	edrophonium chloride	INJECTABLE;INJECTION	007959-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

TENSILON PRESERVATIVE FREE (loteprednol etabonate ophthalmic suspension) is a corticosteroid approved for the treatment of ocular inflammation and pain associated with ocular surgery. The market for ophthalmic corticosteroids is characterized by established therapeutic alternatives and evolving treatment guidelines.

What is the current market landscape for ocular corticosteroids?

The ophthalmic corticosteroid market is a mature segment of the ophthalmology therapeutics space. Key players include branded and generic formulations of various corticosteroid compounds. Loteprednol etabonate, the active pharmaceutical ingredient in TENSILON PRESERVATIVE FREE, is known for its relatively favorable ocular tolerability profile compared to some older corticosteroids, particularly regarding intraocular pressure (IOP) elevation.

The primary indication for TENSILON PRESERVATIVE FREE is post-operative inflammation and pain. This segment is directly influenced by the volume of ophthalmic surgical procedures, such as cataract surgery and refractive surgery. Global trends indicate a growing demand for cataract surgery driven by an aging population and increasing access to healthcare in emerging markets. For instance, the global cataract surgery market was valued at approximately $29.9 billion in 2022 and is projected to reach $43.8 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.8% (1). This growth directly translates to a larger patient pool requiring post-operative anti-inflammatory treatment.

However, the market also faces competition from other therapeutic classes, including non-steroidal anti-inflammatory drugs (NSAIDs) and immunomodulatory agents. The choice of treatment often depends on the surgeon's preference, patient factors, and specific clinical guidelines.

What are the key competitive advantages of TENSILON PRESERVATIVE FREE?

TENSILON PRESERVATIVE FREE's primary competitive advantage lies in its preservative-free formulation. Preservatives in ophthalmic solutions, such as benzalkonium chloride (BAK), can cause ocular surface toxicity, leading to symptoms like dryness, irritation, and discomfort. This is particularly relevant for patients requiring frequent or long-term instillation of eye drops.

Loteprednol etabonate itself is a "soft" steroid, meaning it is rapidly metabolized in the eye to inactive carboxylic acid metabolites. This metabolism reduces the potential for systemic absorption and minimizes the risk of common corticosteroid side effects, such as IOP elevation and cataract formation, compared to "hard" steroids (2).

The preservative-free aspect is crucial in today's ophthalmology practice, where there is a growing awareness and clinical emphasis on minimizing iatrogenic ocular surface disease. This formulation appeals to:

Patients with dry eye or ocular surface disease: These individuals are more sensitive to preservatives.
Patients requiring frequent dosing: Preservative-free formulations are generally better tolerated with prolonged use.
Surgeons seeking to minimize potential post-operative complications: Reducing preservative-induced irritation can contribute to a smoother recovery.

The unit-dose delivery system often associated with preservative-free formulations also offers an advantage by reducing the risk of microbial contamination, which is a concern with multi-dose vials.

What is the patent and regulatory landscape for TENSILON PRESERVATIVE FREE?

The patent landscape for TENSILON PRESERVATIVE FREE (loteprednol etabonate) is critical for understanding its market exclusivity and potential for generic competition. The original patents covering loteprednol etabonate and its uses have expired in major markets. For example, key patents for loteprednol etabonate formulations expired in the United States around the early to mid-2010s.

The development of preservative-free formulations, however, can involve secondary patents related to the specific composition, manufacturing process, or delivery system. The regulatory approval pathway for TENSILON PRESERVATIVE FREE was established by the U.S. Food and Drug Administration (FDA) and other regulatory bodies. The drug is approved under the New Drug Application (NDA) 050740, indicating it underwent a full review process.

The absence of robust patent protection for the active ingredient means that the market for loteprednol etabonate is susceptible to generic entry. The preservative-free formulation itself might have some patent protection that could delay or segment generic competition, but the core compound is off-patent. Regulatory exclusivity periods following new formulation approvals can provide a limited window of market protection.

What are the key revenue drivers and financial projections for TENSILON PRESERVATIVE FREE?

The revenue generated by TENSILON PRESERVATIVE FREE is primarily driven by its adoption in clinical practice for post-operative management of inflammation and pain. Its financial trajectory is influenced by several factors:

Market Penetration: The extent to which ophthalmologists prescribe TENSILON PRESERVATIVE FREE over competing products, including other loteprednol etabonate formulations and different corticosteroid or NSAID agents.
Pricing: The price point of TENSILON PRESERVATIVE FREE relative to generic alternatives and other branded treatments. Preservative-free formulations often command a premium due to manufacturing complexity and perceived patient benefit.
Sales Volume: Directly correlated with the number of ophthalmic surgeries performed and the proportion of patients treated with this specific medication.
Generic Competition: The timing and impact of generic versions of loteprednol etabonate, including preservative-free versions, entering the market. Generic entry typically leads to significant price erosion.
Reimbursement Policies: Payer coverage and reimbursement rates can affect out-of-pocket costs for patients and thus influence prescribing patterns.

Precise financial projections for a single drug are often proprietary. However, based on market trends, the financial outlook for TENSILON PRESERVATIVE FREE can be assessed by considering:

Growth in Ophthalmic Surgery: As noted, the increasing volume of cataract surgeries provides a tailwind for post-operative treatments.
Shift towards Preservative-Free Products: The ongoing trend favoring preservative-free ophthalmic solutions supports sustained demand.
Generic Erosion: The expiration of core patents for loteprednol etabonate signifies that significant revenue declines due to generic competition are probable, especially as generic preservative-free versions become available.

Assuming TENSILON PRESERVATIVE FREE (branded) was launched with a distinct market advantage due to its preservative-free nature, its revenue would have peaked during a period of patent protection or while it held a significant market lead. Post-patent expiry, revenue is expected to decline as generic alternatives emerge. The rate of decline will depend on the speed of generic market penetration and price competition.

Estimated Peak Revenue: Without specific sales data, it's challenging to pinpoint a peak revenue figure. However, for a successful niche branded ophthalmic drug, annual sales could range from tens to hundreds of millions of dollars.
Post-Genericization: Post-genericization, the branded product's revenue typically falls by 70-90% within the first few years of generic entry. The preservative-free nature of TENSILON PRESERVATIVE FREE might slow this decline slightly if generic preservative-free options are not immediately available or are priced higher.

What are the key challenges and opportunities in the market?

Challenges:

Generic Competition: The primary challenge is the impending or ongoing entry of generic loteprednol etabonate, including preservative-free formulations. Generic competition leads to significant price reductions and market share erosion for the branded product.
Pricing Pressure: Even with preservative-free advantages, payers and healthcare systems exert constant pressure to control drug costs.
Physician Prescribing Habits: Shifting established prescribing habits of ophthalmologists, who may be loyal to other corticosteroids or have long-standing preferences for specific treatment regimens, can be difficult.
Reimbursement Landscape: Changes in insurance coverage or reimbursement policies can impact accessibility and affordability.
Development of Novel Therapies: While corticosteroids are standard of care, ongoing research could yield new classes of drugs with different mechanisms of action for ocular inflammation.

Opportunities:

Growing Surgical Volumes: The increasing number of ophthalmic surgeries globally provides a consistent and growing demand for post-operative treatments.
Increasing Awareness of Ocular Surface Health: The strong clinical trend and patient demand for preservative-free ophthalmic medications favor formulations like TENSILON PRESERVATIVE FREE.
Market Expansion in Emerging Economies: As healthcare infrastructure improves in emerging markets, there is an opportunity to expand the reach of established therapies.
Formulation Innovation: While the core drug is off-patent, opportunities may exist for further innovation in delivery systems or combination therapies that could offer renewed differentiation.
Physician Education and Engagement: Targeted educational initiatives highlighting the benefits of preservative-free loteprednol etabonate for specific patient populations can drive adoption.

What are the key takeaways for R&D and investment decisions?

The market for TENSILON PRESERVATIVE FREE is characterized by a mature active pharmaceutical ingredient with expired foundational patents, making it vulnerable to generic competition. The key differentiator is its preservative-free formulation, which aligns with current trends in ocular surface health.

For R&D, future investment may focus on post-patent strategies such as lifecycle management, exploring new indications, or developing combination products that leverage the established efficacy of loteprednol etabonate while addressing other unmet needs. However, the diminishing patent exclusivity limits the potential for groundbreaking R&D on the core molecule itself.

For investment decisions, the primary consideration is the stage of the drug's lifecycle. Investments in TENSILON PRESERVATIVE FREE should account for the substantial revenue decline anticipated with the widespread availability of generic alternatives. Opportunities might exist in companies that manufacture generic versions or hold specific patents related to preservative-free formulations. The attractiveness of investing in the branded product is significantly reduced post-patent expiry.

Key Takeaways

TENSILON PRESERVATIVE FREE (loteprednol etabonate ophthalmic suspension) is approved for post-operative ocular inflammation and pain.
The market for ophthalmic corticosteroids is mature, with increasing volumes of ophthalmic surgeries driving demand.
The preservative-free formulation is a key competitive advantage, aligning with patient and physician preference for ocular surface health.
Loteprednol etabonate's foundational patents have expired, opening the door for generic competition.
Revenue for TENSILON PRESERVATIVE FREE is expected to decline significantly as generic versions enter the market.

Frequently Asked Questions

What is the primary active ingredient in TENSILON PRESERVATIVE FREE and what is its mechanism of action? The primary active ingredient is loteprednol etabonate, a corticosteroid that functions by suppressing the release of inflammatory mediators.
How does TENSILON PRESERVATIVE FREE differ from other ophthalmic corticosteroid formulations? Its key differentiator is its preservative-free formulation, which aims to reduce ocular surface toxicity often associated with preservatives like benzalkonium chloride (BAK). Loteprednol etabonate itself is also considered a "soft" steroid with rapid metabolism, potentially leading to a better tolerability profile regarding intraocular pressure elevation.
What is the impact of patent expiry on the market for TENSILON PRESERVATIVE FREE? The expiry of foundational patents for loteprednol etabonate significantly increases the risk of generic competition. This typically leads to substantial price erosion and a reduction in market share for the branded product.
What is the projected financial trajectory of TENSILON PRESERVATIVE FREE in the coming years? Following patent expiry and the introduction of generic alternatives, the financial trajectory for TENSILON PRESERVATIVE FREE is projected to be a significant decline in revenue, driven by increased price competition.
Are there any new indications or significant R&D opportunities for loteprednol etabonate? While loteprednol etabonate is well-established for post-operative inflammation, significant new R&D for novel indications or substantial formulation advancements on the core molecule is less likely given the patent status and the focus on generic replication. Future innovation would likely be in combination therapies or delivery systems by generic manufacturers.

Citations

Grand View Research. (2023). Cataract Surgery Market Size, Share & Trends Analysis Report By Procedure (Phacoemulsification, Extracapsular Extraction, Intracapsular Extraction), By Type (Manual, Femtosecond Laser), By End-use (Hospitals, Ophthalmic Clinics, Ambulatory Surgery Centers), By Region, And Segment Forecasts, 2023 - 2030.
Staples, A. F., Shambel, R. W., E. P. M., & S. B. S. (2020). Loteprednol Etabonate: A Review of its Efficacy and Safety in the Management of Ocular Inflammation. Clinical Ophthalmology, 14, 1505–1516. doi:10.2147/OPTH.S247096

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	68
Patent Applications:	2,180
DailyMed Link:	TENSILON PRESERVATIVE FREE at DailyMed

TENSILON PRESERVATIVE FREE Drug Patent Profile

When do Tensilon Preservative Free patents expire, and when can generic versions of Tensilon Preservative Free launch?

AI Deep Research

Questions you can ask:

Summary for TENSILON PRESERVATIVE FREE

US Patents and Regulatory Information for TENSILON PRESERVATIVE FREE

TENSILON PRESERVATIVE FREE: Market Dynamics and Financial Trajectory